Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
<p>Abstract</p> <p>Background</p> <p>Myeloperoxidase (MPO) is a marker of plaque vulnerability and a mechanistic bridge between inflammation and cardiovascular disease, and thus is a suitable target for therapeutic strategy against cardiovascular disease.</p> <...
Main Authors: | Minichilli Fabrizio, Bigazzi Federico, Sbrana Francesco, Puntoni Mariarita, Ferdeghini Ezio, Sampietro Tiziana |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-10-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | http://www.lipidworld.com/content/10/1/185 |
Similar Items
-
Case Report: Liver Transplantation in Homozygous Familial Hypercholesterolemia (HoFH)—Long-Term Follow-Up of a Patient and Literature Review
by: Matej Mlinaric, et al.
Published: (2020-10-01) -
Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis
by: Akl C. Fahed, et al.
Published: (2012-11-01) -
Platelet aggregation and lipoprotein levels in a patient with familial hypercholescholesterolemia after selective LDL-apheresis
by: Madalena Nunes da Silva Pares, et al. -
The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia: Seven patients' experience at a DALI apheresis center
by: Muhammet Bulut, et al.
Published: (2020-01-01) -
Extracorporeal LDL-Cholesterol Elimination in the Treatment of Severe Familial Hypercholesterolemia
by: Milan Bláha
Published: (2003-01-01)